Publicacións en colaboración con investigadores/as de University of Birmingham (111)

2023

  1. Cohort profile: the ESC EURObservational Research Programme Non-ST-segment elevation myocardial infraction (NSTEMI) Registry

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 9, Núm. 1, pp. 8-15

2022

  1. Adherence to the “Atrial fibrillation Better Care” (ABC) pathway in patients with atrial fibrillation and cancer: A report from the ESC-EHRA EURObservational Research Programme in atrial fibrillation (EORP-AF) General Long-Term Registry

    European Journal of Internal Medicine, Vol. 105, pp. 54-62

  2. Sample size requirement in trials that use the composite endpoint major adverse cardiovascular events (MACE): new insights

    Trials, Vol. 23, Núm. 1

2019

  1. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: A joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)

    Europace, Vol. 21, Núm. 2, pp. 192-193

  2. European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS)

    Europace, Vol. 21, Núm. 1, pp. 7-8

2018

  1. Enhancing the ‘real world’ prediction of cardiovascular events and major bleeding with the CHA 2 DS 2 -VASc and HAS-BLED scores using multiple biomarkers

    Annals of Medicine, Vol. 50, Núm. 1, pp. 26-34

  2. A Propensity Score Matched Comparison of Clinical Outcomes in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Comparing the “Real-World” vs Clinical Trials

    Mayo Clinic Proceedings, Vol. 93, Núm. 8, pp. 1065-1073

  3. Antiplatelet therapy combined with acenocoumarol in relation to major bleeding, ischaemic stroke and mortality

    International Journal of Clinical Practice, Vol. 72, Núm. 3

  4. Comparison of the 2MACE and TIMI-AF scores for composite clinical outcomes in anticoagulated atrial fibrillation patients

    Circulation Journal, Vol. 82, Núm. 5, pp. 1286-1292

  5. Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: A report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry

    Europace, Vol. 20, Núm. 5, pp. 747-757

  6. Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated “Real-World” in Patients With Atrial Fibrillation

    American Journal of Cardiology, Vol. 122, Núm. 5, pp. 785-792

  7. Estimated absolute effects on efficacy and safety outcomes of using non-vitamin K antagonist oral anticoagulants in ‘real-world’ atrial fibrillation patients: A comparison with optimally acenocoumarol anticoagulated patients

    International Journal of Cardiology, Vol. 254, pp. 125-131

  8. European Heart Rhythm Association (EHRA) position paper on arrhythmia management and device therapies in endocrine disorders, endorsed by Asia Pacific Heart Rhythm Society (APHRS) and Latin American Heart Rhythm Society (LAHRS)

    Europace, Vol. 20, Núm. 6, pp. 895-896

  9. Left atrial thrombus resolution in non-valvular atrial fibrillation or flutter: biomarker substudy results from a prospective study with rivaroxaban (X-TRA)

    Annals of Medicine, Vol. 50, Núm. 6, pp. 511-518

  10. Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation

    European Journal of Clinical Investigation, Vol. 48, Núm. 6

  11. Predicting bleeding events in anticoagulated patients with atrial fibrillation: A comparison between the HAS-BLED and GARFIELD-AF bleeding scores

    Journal of the American Heart Association, Vol. 7, Núm. 18

  12. Prediction of long-term net clinical outcomes using the TIMI-AF score: Comparison with CHA2DS2-VASc and HAS-BLED

    American Heart Journal, Vol. 197, pp. 27-34

  13. Quality of oral anticoagulation with Vitamin K antagonists in 'real-world' patients with atrial fibrillation: A report from the prospective multicentre FANTASIIA registry

    Europace, Vol. 20, Núm. 9, pp. 1435-1441

  14. Reduced Time in Therapeutic Range and Higher Mortality in Atrial Fibrillation Patients Taking Acenocoumarol

    Clinical Therapeutics, Vol. 40, Núm. 1, pp. 114-122

  15. Relation of Renal Dysfunction to Quality of Anticoagulation Control in Patients with Atrial Fibrillation: The FANTASIIA Registry

    Thrombosis and Haemostasis, Vol. 118, Núm. 2, pp. 279-287